Evidence map›Paper›PMID 29103201›Full record

ArticlePathology oncology research : POR2019

Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer.

Laszló Zoltan, Robert Farkas, Andrew V Schally, Eva Pozsgai, Andras Papp, Laura Bognár, Tamas Tornoczki, Laszlo Mangel, Szabolcs Bellyei

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Toxicological research · 2024
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Laszló ZoltanDepartment of Oncology, University of Pécs, Edesanyak street 17, Pécs, 7624, Hungary.
Robert FarkasDepartment of Oncology, University of Pécs, Edesanyak street 17, Pécs, 7624, Hungary.
Andrew V SchallyDepartment of Biochemistry and Medical Chemistry, University of Pécs, Pécs, Hungary.
Eva PozsgaiDepartment of Biochemistry and Medical Chemistry, University of Pécs, Pécs, Hungary.
Andras PappDepartment of Biochemistry and Medical Chemistry, University of Pécs, Pécs, Hungary.
Laura BognárDepartment of Biochemistry and Medical Chemistry, University of Pécs, Pécs, Hungary.
Tamas TornoczkiDepartment of Biochemistry and Medical Chemistry, University of Pécs, Pécs, Hungary.
Laszlo MangelDepartment of Oncology, University of Pécs, Edesanyak street 17, Pécs, 7624, Hungary.
Szabolcs BellyeiDepartment of Oncology, University of Pécs, Edesanyak street 17, Pécs, 7624, Hungary. bellyeisz@gmail.com.
University of Pecs · HUSouth Florida Veterans Affairs Foundation for Research and Education · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the relationship between the intensity of biomarker expression and the response to radiochemotherapy in patients with advanced esophageal squamous cell cancer (ESCC). Ninety-two patients with locally advanced ESCC were examined retrospectively. Pre-treatment tumor samples were stained for proteins SOUL, Hsp 16.2, Growth Hormone-Releasing Hormone Receptor (GHRH-R) and p-Akt using immunhistochemistry methods. Kaplan-Meier curves were used to show the relationship between intensity of expression of biomarkers and clinical parameters and 3-year OS. A significant correlation was found between high intensity staining for Hsp 16.2, p-Akt and SOUL and poor response to NRCT. Application of a higher dose of radiation and higher dose of cisplatin resulted in better clinical and histopathological responses, respectively. Among the clinical parameters, the localization of the tumor in the upper-third of the esophagus and less than 10% weight loss were independent prognostic factors for increased 3-year OS. Hsp16.2, p-Akt and SOUL are predictors of negative response to NRCT, therefore these biomarkers may become promising targets for therapy. Furthermore, level of expression of p-Akt, weight loss and the localization of the tumor are significant factors in the prediction of OS in ESCC.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellChemoradiotherapyEsophageal NeoplasmsFemaleFollow-Up StudiesHeme-Binding ProteinsHemeproteinsHumansIntracellular Signaling Peptides and ProteinsMaleMiddle AgedPregnancy ProteinsPrognosisProto-Oncogene Proteins c-aktRetrospective StudiesAKT1 protein, humanBiomarkers, TumorHEBP2 protein, humanHeme-Binding ProteinsHemeproteinsHSPB11 protein, humanIntracellular Signaling Peptides and ProteinsPregnancy ProteinsProto-Oncogene Proteins c-aktAKTEsopageal cancerPredictiv factorsRadiochemotherapySmall heat shock protein

Identifiers

PMID29103201
OpenAlexW2765362381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.